Dosimetric Effects of Dynamic Jaw Tracking and Collimator Angle Optimization in Non-Coplanar Cranial Arc Radiotherapy

The stereotactic treatment of single cranial targets using noncoplanar volumetric modulated arc therapy (VMAT) allows for effective dose delivery to the target, while sparing normal brain tissue. In this study, the dosimetric effect of adding dynamic jaw tracking and automatic collimator angle selection in the optimization of single target cranial VMAT plans was investigated. Twenty-two cranial targets, previously treated with VMAT without dynamic jaw tracking and automatic collimator angle optimization (CAO) were chosen for replanning. Target volumes ranged from 0.441cc to 25.863cc with doses between 18Gy and 30Gy delivered in 1 to 5 fractions. Original plans were reoptimized with automatic CAO, keeping all other objectives the same (CAO plans). Next, original plans were reoptimized with both dynamic jaw tracking and CAO (DJT plans). Original, CAO, and DJT target doses were compared using the Paddick gradient index (GI) and the Paddick inverse conformity index (ICI), while normal tissue dose was compared using the volume of the normal brain receiving 5Gy, 10Gy, and 12Gy. The normal tissue volume was normalized to target size to allow cross comparison between plans. A one-sided t-test was performed to determine whether the changes in the plan metrics were statistically significant. CAO plans had improved GIs compared to the originals (p = 0.03) with insignificant changes in other plan metrics (p > 0.20). The addition of dynamic jaw tracking in DJT plans greatly improved ICIs and normal brain metrics (p < 0.01) compared to the CAO plans with minor improvement in ICIs (p = 0.07). The combined effect of adding dynamic jaw tracking and collimator optimization led to improvements in all metrics of the DJT plans when compared to the original (p < 0.02). The addition of dynamic jaw tracking and CAO led to improvements in both target and normal tissue dose metrics for single-target noncoplanar cranial VMAT plans.